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Background: Asthma is a complex disease characterized by hyperresponsiveness, obstruction and inflammation of
the airways. To date, several studies using different approaches as candidate genes approach, genome wide
association studies, linkage analysis and genomic expression leaded to the identification of over 300 genes involved
in asthma pathophysiology. Combining results from two studies of genomic expression, this study aims to perform
an association analysis between genes differently expressed in bronchial biopsies of asthmatics compared to
controls and asthma-related phenotypes using the same French-Canadian Caucasian population.
Results: Before correction, 31 of the 85 genes selected were associated with at least one asthma-related phenotype.
We found four genes that survived the correction for multiple testing. The rs11630178 in aggrecan gene (AGC1) is
associated with atopy (p=0.0003) and atopic asthma (p=0.0001), the rs1247653 in the interferon alpha-inducible
protein 6 (IFI6), the rs1119529 in adrenergic, alpha-2A-, receptor (ADRA2A) and the rs13103321 in the alcohol
dehydrogenase 1B (class I), beta polypeptide (ADH1B), are associated with asthma (p=0.019; 0.01 and 0.002
respectively).
Conclusion: To our knowledge, this is the first time those genes are associated with asthma and related traits.
Consequently, our study confirms that genetic and expression studies are complementary to identify new candidate
genes and to investigate their role to improve the comprehension of the complexity of asthma pathophysiology.
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Asthma is a complex disease which is characterized by
hyperresponsiveness, obstruction and inflammation of the
airways and is modulated by the interaction of genetic and
environmental factors [1]. The appearance of an immune
response and of a remodeling process, which implicates
structural and inflammatory cells, dictates the develop-
ment, the severity and the chronicity of asthma [2]. Atopy,
which also shows a genetic component, is characterized
by the excessive production of immunoglobulin E in re-
sponse to environmental allergens and is an important
risk factor of asthma [3]. Using candidate genes approach,
genome wide association studies, linkage analysis or gen-
omic expression, studies of the last decades revealed that* Correspondence: catherine.laprise@uqac.ca
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distribution, and reproduction in any mediumthe pathophysiology of asthma is related with more than
300 genes [4,5]. Indeed, several studies showed that
microarrays are a relevant tool to highlight genes that are
implicated in the different processes occurring during
asthma. [6,7] This study aims firstly to demonstrate that
expression and genetic association studies complement
each other and secondly to test the hypothesis that differ-
ences in the expression of several genes identified in the
studies of Laprise et al. [8] and Chamberland et al. [9]
could be caused by genetic variants. To achieve this, we
combined the results of Laprise et al. and Chamberland
et al. and performed association analysis between the dif-
ferently expressed genes and asthma-related phenotypes
in the family sample of Saguenay–Lac-St-Jean (SLSJ). The
present study identified four significantly associated genes,
which are the aggrecan gene (AGC1) the interferon alpha-
inducible protein 6 (IFI6), the adrenergic, alpha-2A-, re-
ceptor (ADRA2A) and the alcohol dehydrogenase 1B
(class I), beta polypeptide (ADH1B).ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Selection of genes
The selection of genes was made according to the results
of two previous studies of Laprise et al. and Chamberland
et al. [8,9]. Both studies included bronchial biopsies from
four asthmatic subjects and four controls (from the Re-
spiratory Health Network biobank of the Fonds de la
recherche du Québec en santé (FRQS)) and aimed to
identify differently expressed genes related to asthma. The
study of Laprise et al. (Series GSE15823 on GEO) used
the U95Av2 array and a t-test with Bonferroni correction
with a fold change threshold of 2.0, whereas Chamberland
et al. (Series GSE41649 on GEO) used the U133A array
and Smyth’s moderated t-test with a fold change threshold
of 1.8 as selection criteria. Both of them had a signification
level at 0.05. Those two studies allowed to identify a total
of 100 differently expressed genes and classified them in
13 functional groups (see Table 1).
For the present study, some of the 100 genes were not
considered for the following reasons: 1) in the first func-
tional group named immune signaling molecules (Table 1),Table 1 Differently expressed genes in two microarrays
studies using bronchial tissues of asthmatic and control
subjects
Functional category Genes
Immune signaling
molecules
CX3CR1*†, IL7R†, CD14*†, SFRP1†, SCYA21,
SDF1, TNFRSF7, TRA@, CD19, ALOX15*†,
NOS2A†, SCYA5, IL2RB†, IL1R2*†
Extracellular proteins COL11A1, FMOD, MUC5AC£, MUC2£, COL2A1,
AGC1, FBLN1, GPC3, MUC4£, SFRP4
Immune response IGKC, HLA-DPB1*, HLA-DQA1*, HLA-DQB1*,
HLA-DRB4, TRBA£, MS4A1, IGHM, IGLJ3,
CEACAM5, ERAP2, IGHG1*, IGJ, IGLA, IGKV1D-13
Intracellular signaling PTPRC,IFI6, ARHGEF16, PSPHL, GNB2, SYK£,
PPP1R3C, PHLDA1, TYROBP, FKBP8, PIM2, FLRT3
Proteolytic enzymes CPA3*, GZMA, CTSC, CTSG£, PSMA6, TPSB1£,
SERPINB2, SERPINB4*, SPINK5
Transmembrane
proteins
TM4SF3, KLRC3, LGALS7, NKG7, ARHGAP4,
ADRA2A, CLCA2, CLDN10, KCNJ16
Free radical
metabolism
GPX3, GSTA2, CYBA*, CYBB, NQO1*†
Gene transcription TCF21, ZNF38, LDB1, MAF, STAT5A
Cell growth and
proliferation
GAS1, IGFBP6, CORO1A, TRIM16, EMP3, OGN,
S100A14, S100P, SFN
Cell adhesion molecules ITGB2, POSTN*
Complement
components
C1QB, C7£, CFD
Metabolic enzymes RBP4, ALDH3A1, FA2H, ADH1B, PIK3R1
Structural proteins KRT23, TNC£
* Genes associated with asthma, atopy or atopic asthma.
† Association between these genes and asthma or asthma-related phenotype
(atopy or allergic asthma) was already investigated in other articles using the
SLSJ familial asthma study [10-12,45].
£ Protein related to asthma.9 genes (CX3CR1, IL7R, CD14, SFRP1, ALOX15, NOS2A,
IL2RB, NQO1 and IL1R2) were already included in previ-
ous studies and consequently removed for the present
study [10-12]; 2) no SNP for the SDF1, COROA1 and SFN
genes were available in the Illumina 610KQuad array (gen-
ome wide data used for the present study); 3) the TRA@
and TRB@ regions were not included in the present study
as they identify loci and contained several genes and 4) no
reference sequence was available for the IGHM gene. Con-
sequently, a total of 85 genes were included in this genetic
association study.
Sample
The sample comprises 253 asthmatic probands and their
family members (a total of 1284 subjects) from SLSJ, a
region of the province of Quebec, Canada (see Table 2).
This French-Canadian population is known for its
founder effect and has wide conserved chromosomal
regions, which can facilitate the identification of genes
associated with complex traits [13]. In this family collec-
tion, 47% present asthma, 53% present atopy, and 34%Table 2 Clinical characteristics of the French-Canadian
family study
Probands a Family members
n = 253 n = 1031
Male: Female ratio 1 : 1.1 1 : 1.2
Mean age, yr (range) 18 (3–50) 44 (2–93)
Smoking status, n (%)
Never 211 (85) 473 (47)
Ex-smoker 12 (5) 342 (34)
Smoker 25 (10) 197 (19)
FEV1, % predicted (SD)
b 92.7 (15.7) 94.6 (20.3)
PC20, mg/ml (SD)
c 2.53 (3.51) 10.06 (4.97)
Serum IgE in μg/l (SD) d 254.2 (4.9) 112.4 (4.4)
Number of persons with
subphenotypes (%)
Asthma e 253 (100) 378 (37)
Atopy f 200 (79) 509 (49)
Atopic asthma
(Asthma + Atopy)
200 (79) 257 (25)
a Probands are first affected family member recruited in the familial collection
and family members refers to other family members who joined the study.
b FEV1 = Mean calculated for the forced expiratory volume in one second
evaluated for 217 probands and 770 family members.
c PC20 = Provocative concentration of methacholine that induces a 20% fall in
FEV1. Geometric mean and SD evaluated for 192 probands and 711 family
members.
d IgE = Immunoglobulin E serum concentration. Geometric mean and SD
evaluated for 237 probands and 820 family members.
e Present asthma or past documented clinical history of asthma. The reported
mean age of onset is 7 years among the probands and 22 years among the
asthmatic family members. Asthma phenotype was evaluated for 1022
subjects.
f Defined as at least one positive response on skin prick test (wheal diameter
> 3 mm at 10 minutes). Atopy phenotype was evaluated for 997 subjects.
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described in previous publications [14,15]. Phenotypes
were defined following the American Thoracic Society’s
criteria [16]. Asthma was defined if the subject had an
asthma diagnosis by a physician or if he showed a posi-
tive methacholine provocation test (PC20 > 8 mg/ml)
combined with asthma-related symptoms. Atopy was
defined as a positive response (wheal diameter ≥ 3 mm
at 10 min) for at least one allergen to the skin prick test.
Atopic asthma was defined as a combination of both
asthma and atopy. This research project was reviewed
and approved by the institutional ethic committee of the
Université du Québec à Chicoutimi. The written
informed consent for participation in the study was
obtained from participants or, where participants are
children, from a parent.
Genotyping
The sample used in the present study was genotyped
using Illumina 610KQuad array (Illumina, San Diego,
USA) at the Centre National de Génotypage (CNG,
Evry, France) [17]. A total of 1217 SNPs that are
located in a ± 10 kb area from the 85 selected genes
and fulfilling the following quality control criteria were
considered in the analyses: call rate ≥ 95%, minor allele
frequency ≥ 5%, Hardy-Weinberg equilibrium p value ≥
5% and Mendelian errors ≤ 1%. Genotypes were
extracted from the genome wide association study
(GWAS) data using PLINK software (http://pngu.mgh.
harvard.edu/~purcell/plink/, version 1.07).
Statistical analyses
To identify associations between SNPs and asthma-related
phenotypes, transmission disequilibrium was analyzed
using the Family-Based Association Tests software
(FBAT) (version 2.0.3, http://www.biostat.harvard.edu/
~fbat/default.thml). SNP associations were investigated
under an additive genetic model and with the empirical
variance estimator “-e” to account for the inclusion of
multiple affected family members [18]. All the associations
of SNPs obtained had to survive a multiple test correction
for the number of independent tagSNPs [19] and theTable 3 Associated SNPs after correction with asthma-related
Gene/ Corr.
thresholda
SNP Allele
MAFb
Asthma
Famc Z P v
AGC1 /0.001 rs11630178 T/C 0.34 99 2.69 0.0
IFI6 /0.025 rs11247653 A/G 0.43 133 −2.35 0.0
ADRA2A /0.025 rs11195299 G/A 0.06 56 −2.59 0.0
ADH1B /0.003 rs13103321 G/T 0.48 135 −3.04 0.0
a Corrected threshold for multiple testing (considering independent tagSNPs and p
b Minor allele frequency observed in the sample.
c Number of families that contributed to the test.
SNP= Single nucleotide polymorphism; MAF= Minor allele frequency; Fam= Familienumber of independent phenotypes, which was identified
as two using a matrix spectral decomposition (matSpD)
(http://gump.qimr.edu.au/general/daleN/matSpD/).
Results
For the analyses, a total of 1217 SNPs located in the 85
studied genes were tested individually for association
with asthma, atopy, and atopic asthma. Before correc-
tion, 95 SNPs located in 30 genes (CD19COL11A1,
MUC2, COL2A1, AGC1, FBLN, HLA-DPB1, MS4A1,
CEACAM5, IGHG1, IGLA, PTPRC, IFI6, SYK, CTSC,
PSMA6, SPINK5, KLRC3, ADRA2A, CLCA2, KCNJ16,
CYBA, ZNF38, ITGB2, C7, ALDH3A1, FA2H, ADH1B,
PIK3R1 and TNC) were associated with asthma-related
phenotypes (data not shown, see Additional file 1).
After correction for independent tagSNPs and pheno-
types, four SNPs in the AGC1, IFI6, ADRA2A and
ADH1B genes remained associated (see Table 3). The
rs11630178 in the AGC1 gene is associated with atopy
(p=0.0003) and atopic asthma (p=0.0001), the rs1247653
located in the IFI6 gene (p=0.019), the rs1119529 in the
ADRA2A gene (p=0.009) and the rs13103321 in the
ADH1B gene (p=0.002), are associated with asthma.
Discussion
This study aimed to demonstrate that gene expression
studies may lead to the identification of genetic determi-
nants. Indeed, although all expression differences cannot
be explained by a genetic variant, it is possible that dif-
ferential expression is related to a SNP in a regulatory
region or in the promoter [20]. As the genotypes for the
SLSJ family study were available from the GWAS data,
we investigated the association of SNPs located in genes
that are differently expressed in bronchial biopsies of
atopic asthmatics compared to controls from two previ-
ous publications and asthma-related phenotypes [8,9].
We showed that four genes are genetically associated
with asthma or asthma-related phenotypes (the AGC1
gene associated with atopy and atopic asthma, the IFI6,
ADRA2A and ADH1B genes associated with asthma).
Like the majority of asthma associated SNPs, the
variants associated in the present study are located inphenotypes
Atopy Atopic asthma
alue Fam Z P value Fam Z P value
070 82 3.59 0.0003 85 3.90 0.0001
186 109 −1.77 0.0770 110 −1.90 0.0570
097 54 −0.79 0.4283 53 −1.92 0.0527
024 114 −2.57 0.0103 114 −2.62 0.0088
henotypes).
s.
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may lead to the suppression of critical steps (such as the
binding of splicing factors or DNA polymerase) and to
the abolition or creation of a binding site causing alter-
ation in gene expression [21].
The AGC1 gene, located in the chromosomal region
15q26, is coding for the aggrecan, a major component of
the extracellular matrix of the cartilage that binds with
tenascins [22]. More specifically, it binds to the type C
tenascins that are upregulated in acute and chronic in-
flammatory diseases [23]. In asthmatic subjects, there is
an abnormal deposition of tenascin C on the basal mem-
brane, which leads to a decrease of the airway lumen [24].
Tenascin C is implicated in allergies and increases during
seasonal atopic asthma [25]. Three SNPs in the tenascin C
gene, including a coding SNP (GLN/1978/ARG), were
associated with atopy in our study before correction (data
not shown). The implication of the tenascin C in the
atopic mechanisms supports its association with atopy
and atopic asthma phenotypes in our study, but this gene
was also associated with asthma in other studies [26]. In
the literature, the AGC1 gene was mostly associated with
skeleton and spinal cord diseases [27,28].
The IFI6 gene is located on the chromosome 1 and
codes for an interferon-induced protein that regulates
the apoptosis process. This gene is involved in the treat-
ment of myeloma and other malignancy diseases by its
antiapoptotic activity [29]. There is no function estab-
lished for this gene in respiratory disorder except for its
implication in tract infection caused by the respiratory
syncytial virus (RSV) [30]. As RSV leads to the inflam-
mation of the epithelium in affected patients and as a
previous GWAS demonstrated that genes implicated in
the epithelial function are strongly associated with
asthma [17], the IFI6 gene could play a role in asthma
through the modulation of the epithelium structure.
The ADRA2A gene, mapped on the 10q23 chromo-
somal region, codes for the A subtype of the adrenergic g
protein-coupled receptors family. This family plays a role
in the regulation of neurotransmitters, the production of
normal neurons, and is implicated in the cardiovascular
and the central nervous systems [31]. The B subtype of
the receptor is known to be a biomarker in asthma and
its agonists are used as therapeutic molecules as bronch-
oconstriction regulators [32,33]. Several studies asso-
ciated SNPs in the ADRA2B gene with asthma and atopic
diseases [34-37]. In the respiratory system, the activation
of the adrenergic alpha-2A-receptor regulates the recov-
ery of the cholinergic outflow to the airways in response
to repeated allergen exposition and also leads to the re-
lease of proinflammatory cytokines [32,38]. This gene is
also involved in the regulation of mood, response to
stress, anxiety and autonomic function [39,40]. Conse-
quently, interactions between physiological factors andemotions may modulate the severity and the symptoms
of asthma at least partially through the ADRA2A gene.
The ADH1B gene is located on the long arm of the
chromosome 4 and codes for the beta unit of class I al-
cohol dehydrogenase. This enzyme catalyzes the oxida-
tion of alcohol to acetaldehyde [41]. SNPs in the alcohol
dehydrogenase and the acetaldehyde dehydrogenase
genes are involved in alcohol-induced hypersensitivity
[42,43]. Moreover, the inhalation of acetaldehyde (alco-
hol) and a fast metabolism of ethanol can lead to a
bronchoconstriction in asthmatic subjects [44]. There-
fore, the ADH1B gene seems to be involved in an in-
crease of airway obstruction in asthma by its effects on
the alcohol metabolism.
Conclusion
The association analysis on genes differently expressed
in microarray studies of bronchial biopsies obtained
from asthmatic and control subjects allowed confirming
the association of four new genes to asthma and/or al-
lergy. The known functions of these genes suggest that
they could play a significant role in the pathogenesis of
asthma. On the 100 genes identified as differently
expressed in the Laprise et al. and Chamberland et al.
studies, the combination of the four association studies
performed by our team associated 9 genes after correc-
tion for multiple testing (9%). This study illustrates the
potential of combining studies of expression and associ-
ation in order to increase our understanding of the biol-
ogy of complex traits, and more specifically to identify
gene and biological pathways relevant to asthma.
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